<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04037098</url>
  </required_header>
  <id_info>
    <org_study_id>R-2019-785-040</org_study_id>
    <nct_id>NCT04037098</nct_id>
  </id_info>
  <brief_title>Magnesium Lactate in the Reduction of Gestational Diabetes Incidence.</brief_title>
  <official_title>Efficiency and Safety of Magnesium Lactate Administration in the Reduction of Gestational Diabetes Incidence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes, occurs during the second or third trimester of pregnancy, with no prior
      history of diabetes; this entity can be resolved at the end of pregnancy. Magnesium is the
      fourth most abundant mineral in the body, It plays an essential role in the regulation of
      insulin metabolism, in the functions of adenosine triphosphate. In Mexico, the prevalence of
      hypomagnesemia is 36.3% for women. Findings suggesting that magnesium supplementation may be
      a beneficial indication in metabolic glucose disorders. The hypothesis of this study is: that
      Magnesium lactate administration is safe and reduces the incidence of gestational diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: This study aims to evaluate the efficacy and safety of magnesium lactate oral
      administration in reducing the gestational diabetes incidence.

      Design: Randomized, double-blind, placebo-controlled clinical trial.

      Study population: Pregnant women aged 19 to 35 years, in the twelfth week of pregnancy, whit
      hypomagnesemia and without the concomitant disease.

      Study groups: an intervention group and a control group.

      Sample size: It was calculated using a statistical power of 80%, an alpha value of 0.05; 15%
      of the difference in the mean of gestational diabetes incidence control group and
      intervention groups was considered. The estimated sample size was 110 subjects for each
      group.

      Process: All eligible participants according to inclusion and exclusion criteria, will be
      randomized to one of the study groups.

      The intervention group will receive magnesium lactate, 2 tablets orally every 12 hours
      (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium
      requirement; the control group will receive 2 tablets orally every 12 hours of on inert
      placebo for three months plus baseline dietary magnesium requirement.

      The blood concentrations of glucose, triglycerides, magnesium, creatinine, transaminases, and
      thyroid hormones will be measured, as well as the anthropometric measurements, at baseline
      and end conditions. Also, an oral glucose tolerance curve will be realized at the 20th
      gestation week.

      Statistical analysis: Numerical values will be expressed as mean ± standard deviation;
      categorical variables will be expressed as proportions. Differences between the groups were
      estimated by unpaired Student t-test for numerical variables (Mann-Whitney U test for skewed
      data) or Chi-square and Fisher´s exact test for categorical variables. Intragroup differences
      were estimated by paired Student t-test.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study groups:
Intervention group. Women 19 to 35 years of age, in the twelfth week of pregnancy, who will receive magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.
Control group. Women 19 to 35 years of age, in the twelfth week of pregnancy, who will receive 2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Neither the patient nor the treating doctor will know the study group the participant was randomized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased of gestational diabetes incidence</measure>
    <time_frame>Three months.</time_frame>
    <description>The incidence of gestational diabetes will be considered as a decrease, at the small proportion difference of less than 13.4% between the incidence of gestational diabetes in the intervention group and the placebo group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Pregnancy Related</condition>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium lactate, 2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months plus baseline dietary magnesium requirement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets orally every 12 hours of on inert placebo for three months plus baseline dietary magnesium requirement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium lactate.</intervention_name>
    <description>2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months</description>
    <arm_group_label>Magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tablets orally every 12 hours of on inert placebo for three months</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women aged 19 to 35 years.

          -  12th to 14th gestation weeks.

          -  Informed consent of the participant.

        Exclusion Criteria:

          -  Diabetes.

          -  High blood pressure.

          -  Hypertriglyceridemia (&gt;250 g/dL)

          -  Neoplasia disease.

          -  Thyroid disease.

          -  Hepatic disease.

          -  Consumption of alcoholic beverages.

          -  Smoking.

          -  Medication use (thiazide diuretics, anti-blocking agents, calcium antagonists,
             statins, nicotinic acid, phenytoin, valproic acid, antidepressants, beta-adrenergic,
             theophylline, glucocorticoids, in the last year)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando PD Guerrero</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis PD Simental</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerardo PD Martínez</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cludia PD Gamboa</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando PD Guerrero</last_name>
    <phone>526188120997</phone>
    <email>guerrero.romero@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nayeli Vidaca</last_name>
    <phone>526181449045</phone>
    <email>nayelividaca2016@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Biomedical Research Unit. IMSS. Durango</name>
      <address>
        <city>Durango</city>
        <state>Dgo</state>
        <zip>34067</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Mack LR, Tomich PG. Gestational Diabetes: Diagnosis, Classification, and Clinical Care. Obstet Gynecol Clin North Am. 2017 Jun;44(2):207-217. doi: 10.1016/j.ogc.2017.02.002. Review.</citation>
    <PMID>28499531</PMID>
  </reference>
  <reference>
    <citation>Kim C. Maternal outcomes and follow-up after gestational diabetes mellitus. Diabet Med. 2014 Mar;31(3):292-301. doi: 10.1111/dme.12382. Review.</citation>
    <PMID>24341443</PMID>
  </reference>
  <reference>
    <citation>Al-Badri MR, Zantout MS, Azar ST. The role of adipokines in gestational diabetes mellitus. Ther Adv Endocrinol Metab. 2015 Jun;6(3):103-8. doi: 10.1177/2042018815577039. Review.</citation>
    <PMID>26137214</PMID>
  </reference>
  <reference>
    <citation>Fan Y, Xu R, Cai L, Cai L. [Risk factors of gestational diabetes mellitus among the re-birth pregnant women in Xiamen City in 2015-2016]. Wei Sheng Yan Jiu. 2017 Nov;46(6):925-929. Chinese.</citation>
    <PMID>29903201</PMID>
  </reference>
  <reference>
    <citation>Sarrafzadegan N, Khosravi-Boroujeni H, Lotfizadeh M, Pourmogaddas A, Salehi-Abargouei A. Magnesium status and the metabolic syndrome: A systematic review and meta-analysis. Nutrition. 2016 Apr;32(4):409-17. doi: 10.1016/j.nut.2015.09.014. Epub 2015 Oct 23. Review.</citation>
    <PMID>26919891</PMID>
  </reference>
  <reference>
    <citation>Asemi Z, Karamali M, Jamilian M, Foroozanfard F, Bahmani F, Heidarzadeh Z, Benisi-Kohansal S, Surkan PJ, Esmaillzadeh A. Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2015 Jul;102(1):222-9. doi: 10.3945/ajcn.114.098616. Epub 2015 May 27.</citation>
    <PMID>26016859</PMID>
  </reference>
  <reference>
    <citation>Han H, Fang X, Wei X, Liu Y, Jin Z, Chen Q, Fan Z, Aaseth J, Hiyoshi A, He J, Cao Y. Dose-response relationship between dietary magnesium intake, serum magnesium concentration and risk of hypertension: a systematic review and meta-analysis of prospective cohort studies. Nutr J. 2017 May 5;16(1):26. doi: 10.1186/s12937-017-0247-4. Review.</citation>
    <PMID>28476161</PMID>
  </reference>
  <reference>
    <citation>Dalton LM, Ní Fhloinn DM, Gaydadzhieva GT, Mazurkiewicz OM, Leeson H, Wright CP. Magnesium in pregnancy. Nutr Rev. 2016 Sep;74(9):549-57. doi: 10.1093/nutrit/nuw018. Epub 2016 Jul 21. Review.</citation>
    <PMID>27445320</PMID>
  </reference>
  <reference>
    <citation>Makrides M, Crosby DD, Bain E, Crowther CA. Magnesium supplementation in pregnancy. Cochrane Database Syst Rev. 2014 Apr 3;(4):CD000937. doi: 10.1002/14651858.CD000937.pub2. Review.</citation>
    <PMID>24696187</PMID>
  </reference>
  <reference>
    <citation>Guerrero-Romero F, Rodríguez-Morán M. [Oral magnesium supplementation: an adjuvant alternative to facing the worldwide challenge of type 2 diabetes?]. Cir Cir. 2014 May-Jun;82(3):282-9. Spanish.</citation>
    <PMID>25238470</PMID>
  </reference>
  <reference>
    <citation>Morton A. Hypomagnesaemia and pregnancy. Obstet Med. 2018 Jun;11(2):67-72. doi: 10.1177/1753495X17744478. Epub 2018 Mar 7. Review.</citation>
    <PMID>29997688</PMID>
  </reference>
  <reference>
    <citation>Alves JG, de Araújo CA, Pontes IE, Guimarães AC, Ray JG. The BRAzil MAGnesium (BRAMAG) trial: a randomized clinical trial of oral magnesium supplementation in pregnancy for the prevention of preterm birth and perinatal and maternal morbidity. BMC Pregnancy Childbirth. 2014 Jul 8;14:222. doi: 10.1186/1471-2393-14-222.</citation>
    <PMID>25005784</PMID>
  </reference>
  <reference>
    <citation>Dainelli L, Prieto-Patron A, Silva-Zolezzi I, Sosa-Rubi SG, Espino Y Sosa S, Reyes-Muñoz E, Lopez-Ridaura R, Detzel P. Screening and management of gestational diabetes in Mexico: results from a survey of multilocation, multi-health care institution practitioners. Diabetes Metab Syndr Obes. 2018 Apr 5;11:105-116. doi: 10.2147/DMSO.S160658. eCollection 2018.</citation>
    <PMID>29670384</PMID>
  </reference>
  <reference>
    <citation>Ramírez-Torres MA. The importance of gestational diabetes beyond pregnancy. Nutr Rev. 2013 Oct;71 Suppl 1:S37-41. doi: 10.1111/nure.12070. Review.</citation>
    <PMID>24147923</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Fernando Guerrero Romero MD</investigator_full_name>
    <investigator_title>Head of the research unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

